HFPN Strategic Adviser Ed Harding discusses cardiovascular care with Health Europa Quarterly

News & Events

19 January 2022
AUTHOR: HFPN Admin

Ed Harding, Strategic Adviser to the Heart Failure Policy Network (HFPN), recently spoke with Health Europa Quarterly (HEQ) about the key challenges affecting the diagnosis, screening and treatment of heart failure.

In the interview, which is included in issue 20 of the HEQ online publication, Ed outlined how the HFPN was founded and its role in addressing gaps in heart failure care. The conversation also turned to learnings from the inaugural Heart Failure Policy Summit in 2021, which looked at heart failure in light of health inequalities, health system sustainability and the impact of COVID-19.

The key takeaway from the discussion is the need to increase knowledge and awareness of cardiovascular disease, and to make rapid improvements in European heart failure policy. ‘If you look at studies across Europe, we know that we are not very good at helping people who live with established cardiovascular disease,’ says Ed. ‘The message I would convey to anyone reading this article is that their government, or their region, should at least have a position, even if it’s not a strategy, on heart failure.’

Read the full article: https://www.healtheuropa.eu/connecting-care-for-cardiovascular-diseases/112819/

Tagged:

More from News & Events

New guide for regional decision-makers in Spain aims to supp
New guide for regional decision-makers in Spain aims to supp...
10 April 2025
HFPN collaborated with leading experts in Spain to develop a three-step framework to support the transformation of heart failure service in line with the Spanish National Cardiovas...
Read article
Meet our members: Yvan Devaux
Meet our members: Yvan Devaux...
25 March 2025
We spoke to HFPN member Yvan Devaux, Head of the Cardiovascular Research Unit at the Luxembourg Institute of Health....
Read article
The Heart Failure Policy Network is an independent, multidisciplinary platform made possible with financial support from AstraZeneca, Roche Diagnostics, Bayer and Netherlands Heart Institute. The content produced by the Network is not biased toward any specific treatment or therapy. All outputs are guided and endorsed by the Network’s members. All members provide their time for free. The Network is hosted by The Health Policy Partnership.